ArticleFrontiers in pharmacology2026
LTF promotes central nervous system leukemia progression via neutrophil serine proteases.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Central nervous system (CNS) infiltration is a severe complication of acute myeloid leukemia (AML), often leading to relapse and poor prognosis. The underlying mechanisms remain poorly understood, limiting the development of effective targeted therapies. Conventional chemotherapy agents capable of crossing the blood-brain barrier (BBB) carry significant toxicity and fail to eliminate leukemia stem cells. Methods: Using multiple clinical cohorts, we established prognostic prediction model for AML. Using knockdown and overexpression experiments in a mouse leukemia CNS infiltration model, the role of risk factor gene in CNS infiltration was evaluated, along with the attenuating effect of its downstream proteins drug inhibition on leukemia CNS infiltration. Results: We identify Lactoferrin (LTF) as a risk factor associated with poor AML prognosis using a machine learning-based prognostic model. Through Discussion: Our findings establish LTF as a mediator of CNS infiltration in AML and highlight NSP inhibition as a promising therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.